8-K: Kymera Reports Strong Q2, Advances Key Programs

Kymera Therapeutics announced its second quarter 2025 financial results, highlighted by positive Phase 1 data for KT-621, a new strategic partnership with Gilead, and an extended cash runway into late 2028.

Summary

• Net loss for the second quarter of 2025 was $76.6 million, compared to $42.1 million for the second quarter of 2024.
• Collaboration revenues were $11.5 million for the second quarter of 2025, down from $25.7 million for the same period in 2024, due to recognition of all remaining deferred revenue from the Sanofi collaboration.
• Research and development expenses increased to $78.4 million in Q2 2025 from $59.2 million in Q2 2024, driven by increased investment in the STAT6 program, platform, discovery programs, and R&D organization growth.
• Kymera reported approximately $1 billion in cash, cash equivalents, and investments as of July 31, 2025, extending its cash runway into the second half of 2028.
• Positive Phase 1 healthy volunteer data for KT-621 (STAT6 degrader) were reported, surpassing Kymera's target product profile and validating its oral, dupilumab-like profile with robust STAT6 degradation and Th2 biomarker reductions.
• The KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis (AD) patients is on track to report data in the fourth quarter of 2025.
• Doses have been selected for KT-621 Phase 2b trials in AD and asthma, which are on track to initiate in the fourth quarter of 2025 and the first quarter of 2026, respectively.
• IND-enabling studies for KT-579 (IRF5 degrader) are ongoing, with a Phase 1 clinical trial expected to start in early 2026.
• Kymera entered a strategic partnership with Gilead to develop novel oral molecular glue CDK2 degraders, with potential total payments up to $750 million, including up to $85 million in upfront and option exercise payments.
• Sanofi prioritized KT-485 (second-generation IRAK4 degrader) for development, expected to advance into Phase 1 testing next year, resulting in a $20 million milestone payment to Kymera in Q2 2025.

Sentiment

Score: 8

Explanation: The filing presents strong positive clinical data for its lead program, secures a significant new partnership with a major pharmaceutical company, and significantly extends its cash runway, indicating strong operational and financial health despite an increased net loss which is typical for a clinical-stage biotech.

Positives

• Positive Phase 1 healthy volunteer data for KT-621 demonstrated complete STAT6 degradation in blood and skin (>90% mean in blood, complete in blood and skin at MAD doses >= 50mg), reductions of multiple disease-relevant Th2 biomarkers (median TARC reduction up to 37%, median Eotaxin-3 reduction up to 63%), and a safety profile undifferentiated from placebo.
• KT-621 data surpassed Kymera's target product profile and validated its oral, dupilumab-like profile, indicating strong potential for a new class of oral medicines with biologics-like efficacy.
• Successful completion of four-month GLP toxicology studies for KT-621 in NHP and rat, with no observed adverse events at all tested doses and concentrations.
• Secured a strategic partnership with Gilead for CDK2 molecular glue degraders, providing up to $750 million in potential total payments, including up to $85 million in upfront and option exercise payments, validating Kymera's platform and providing significant non-dilutive capital.
• Sanofi prioritized KT-485 (second-generation IRAK4 degrader) for Phase 1 testing next year, leading to a $20 million milestone payment received in Q2 2025, demonstrating continued progress in existing collaborations.
• Strong cash position of approximately $1 billion as of July 31, 2025, extending the cash runway into the second half of 2028, providing financial stability for pipeline advancement.
• Advancement of KT-579 (IRF5 degrader) towards Phase 1 clinical trial in early 2026, expanding the clinical pipeline.
• Doses selected for KT-621 Phase 2b studies in AD and asthma, expected to accelerate development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 indications.

Negatives

• Net loss increased to $76.6 million in Q2 2025 from $42.1 million in Q2 2024, reflecting increased operational expenses.
• Collaboration revenues decreased to $11.5 million in Q2 2025 from $25.7 million in Q2 2024, primarily due to the recognition of all remaining deferred revenue from the Sanofi collaboration.
• Research and development expenses increased significantly to $78.4 million in Q2 2025 from $59.2 million in Q2 2024, indicating higher burn rate.
• Sanofi decided not to advance Kymera's first-generation IRAK4 degrader, KT-474, focusing instead on KT-485.

Risks

• Cross-trial comparisons, such as KT-621 to dupilumab, may not be reliable as no head-to-head trials have been conducted, and data may not be directly comparable due to differences in molecule composition, trial protocols, dosing regimens, and patient populations and characteristics.
• Results from the Phase 1b KT-621 trial may differ from the Phase 1 KT-621 data.
• Preclinical and clinical data, including results from the Phase 1 trial of KT-621, are not predictive of, may be inconsistent with, or more favorable than, data generated from future or ongoing clinical trials of the same product candidate.
• Uncertainties inherent in the initiation, timing, and design of future clinical trials.
• The availability and timing of data from ongoing and future clinical trials and the results of such trials.
• The ability to successfully demonstrate the safety and efficacy of drug candidates.
• The timing and outcome of planned interactions with and submissions to regulatory authorities.
• The availability of funding sufficient for operating expenses and capital expenditure requirements.
• The ability of each party to perform its obligations under the Kymera and Gilead exclusive option and license agreement.
• Whether the parties will be able to successfully conduct and complete preclinical development, clinical development, and commercialization of any drug candidates under the Kymera and Gilead collaboration.
• The unexpected emergence of adverse events or other undesirable side effects during preclinical and clinical development.
• Whether Kymera will be able to fund development activities and achieve development goals, including those under the Kymera and Gilead collaboration.
• Risks and uncertainties relating to the timing and receipt of payments from collaboration partners, including milestone payments and royalties on future potential product sales.

Future Outlook

Kymera expects to report KT-621 BroADen Phase 1b trial data in AD patients in Q4 2025, initiate KT-621 Phase 2b studies in AD and asthma in Q4 2025 and Q1 2026 respectively, and advance KT-579 into Phase 1 clinical testing in early 2026. The company anticipates its cash runway will extend into the second half of 2028, supporting multiple clinical inflection points in its pipeline.

Management Comments

• "The first half of this year has been rich in data and milestones that build upon our scientific achievements and further validate the potential impact of our industry leading oral immunology pipeline."
• "This includes the exceptional data from the healthy volunteer trial for KT-621, our once-a-day oral STAT6 degrader, which exceeded expectations across every measure showing robust target and pathway engagement, as well as safety undifferentiated from placebo."
• "Were continuing to rapidly advance this program, and with the enrollment progress we have made in the KT-621 BroADen Phase 1b trial in AD patients, were on track to share the BroADen study data, and to initiate our first Phase 2b study in AD, both in the fourth quarter."
• "Additionally, were advancing KT-579, our oral IRF5 degrader program with broad clinical promise in areas of high unmet need, on the path to clinical entry early next year."
• "We recently announced two collaboration updates as well, including an exciting new partnership with Gilead focused on our innovative CDK2 molecular glue program, and Sanofis plans to advance our second generation IRAK4 degrader, KT-485, into clinical studies."
• "With $1 billion in cash and an extended cash runway into the second half of 2028, we are well-positioned to deliver on our goals and improve patients lives with a new class of oral medicines with biologics-like profiles."

Industry Context

Kymera Therapeutics is at the forefront of targeted protein degradation (TPD), a rapidly advancing field in biotechnology, focusing on developing oral small molecule degraders for immunological diseases. The strategic partnership with Gilead for CDK2 molecular glue degraders underscores the pharmaceutical industry's growing interest in novel mechanisms for oncology. Kymera's efforts to develop oral therapies with 'biologics-like profiles,' exemplified by KT-621's comparison to dupilumab, reflect a broader industry trend towards more convenient and accessible treatments that can match the efficacy of established injectable biologics, potentially disrupting existing treatment paradigms for chronic conditions like atopic dermatitis and asthma.

Comparison to Industry Standards

• KT-621 demonstrated an impact on Th2 biomarkers in line or superior to dupilumab, with median TARC reduction up to 37% and median Eotaxin-3 reduction up to 63%.
• KT-621 aims for a "dupilumab-like profile" as an oral STAT6 degrader, setting a high benchmark against Dupixent (dupilumab), a leading biologic for atopic dermatitis and asthma.
• In preclinical models of lupus and rheumatoid arthritis (RA), KT-579 was equal or more efficacious than clinically active or marketed small molecule inhibitors and biologics, suggesting competitive potential against current standard-of-care treatments.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, a significant new partnership, and an extended cash runway, which could drive future stock appreciation. The increased net loss is a short-term negative but expected for a growth-stage biotech.
• Patients: Potential for new, convenient, and highly effective oral therapies for immunological diseases such as atopic dermatitis, asthma, lupus, and rheumatoid arthritis, if pipeline candidates prove successful in later trials.
• Employees: Enhanced job security and potential for growth opportunities due to the company's strong financial position and advancing pipeline.
• Partners (Gilead, Sanofi): Strengthened collaborations, with Gilead gaining rights to a novel CDK2 degrader program and Sanofi advancing a second-generation IRAK4 degrader, indicating mutual benefit and progress in their respective pipelines.
• Creditors: Improved financial stability due to significant cash reserves and an extended runway, reducing credit risk.

Next Steps

• Report KT-621 BroADen Phase 1b trial data in Q4 2025.
• Initiate KT-621 Phase 2b study in AD in Q4 2025.
• Initiate KT-621 Phase 2b study in asthma in Q1 2026.
• Advance KT-579 into Phase 1 clinical testing in early 2026.
• Present KT-621 Phase 1 healthy volunteer data at the European Respiratory Society (ERS) Congress (September 27-October 1, 2025).
• Present KT-621 preclinical data at the European Academy of Dermatology and Venereology (EADV) Congress (September 17-20, 2025).
• Share new KT-579 preclinical data at the American College of Rheumatology (ACR) Annual Meeting (October 24-29, 2025).
• Sanofi to advance KT-485 into Phase 1 testing next year.

Key Dates

Recommendation

The filing demonstrates significant progress across Kymera's pipeline, particularly with the highly positive Phase 1 data for KT-621, which exceeded expectations and showed a 'dupilumab-like' profile for an oral drug. The new strategic partnership with Gilead provides substantial non-dilutive capital and validates Kymera's platform, while the extended cash runway into late 2028 significantly de-risks future operations. Although the net loss increased, this is typical for a clinical-stage biotech investing heavily in R&D. The combination of strong clinical validation, strategic partnerships, and robust financial health positions Kymera for significant future growth and makes it an attractive investment.

Keywords

Kymera Therapeutics, KYMR, biotechnology, targeted protein degradation, STAT6 degrader, KT-621, atopic dermatitis, asthma, IRF5 degrader, KT-579, CDK2 degrader, molecular glue, Gilead, Sanofi, IRAK4 degrader, KT-485, clinical trials, Phase 1, Phase 2b, financial results, Q2 2025, cash runway, immunological diseases, Th2 inflammation, protein degraders